BREAST CANCER

Mohammad Jahanzeb, MD, discusses the designs of landmark trials in early HER2-positive targeted therapy and the adverse events associated with those treatments.

Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, discusses the ongoing MONARCH and neoMONARCH studies in breast cancer.

According to a retrospective 4.5-year study of patients who had commercial and Medicare supplemental coverage, healthcare resource use and costs remain high among patients with metastatic triple-negative breast cancer.

Elizabeth A. Mittendorf, MD, PhD, discusses the immunotherapy combinations currently being investigated in the treatment of breast cancer.

Kimberly Blackwell, MD,&nbsp;discusses the results of the recent phase III OLYMPIAD trial, which showed olaparib (Lynparza) improved progression-free survival (PFS) versus standard chemotherapy in patients with <em>BRCA</em>-positive breast cancer.

Kelly K. Hunt, MD, professor of Surgery, and chair, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses incorporating biologic factors into breast cancer staging.

Hope Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses targeting the androgen receptor in breast cancer.

The addition of CDK4/6 and mTOR inhibitors to standard endocrine therapy has significantly improved outcomes in patients with hormone receptor (HR)&ndash;positive, HER2-negative advanced breast cancer.

Larry Norton, MD, says the so-called butterfly effect, in which a small creature can cause something on the scale of an earthquake merely by flapping its wings, is fodder for debate on whether the digital revolution in medicine can deliver on its promise for precision medicine.

Pat Whitworth, MD, discusses how surgeons remain involved in genetic counseling to meet the immense unmet need that exists for patients with breast cancer.

Treatment with trastuzumab (Herceptin) has shown such a benefit in the&nbsp;treatment of patients with HER2-positive breast cancer that it is now the&nbsp;standard of care despite its association with cardiotoxicity. As such, researchers&nbsp;have taken to searching for ways to lessen or prevent the incidence of&nbsp;cardiac events in trials with trastuzumab.&nbsp;

Adam M. Brufsky, MD, PhD, discusses considerations for using denosumab as well as zoledronic acid as in patients with breast cancer.

The addition of the CDK4/6 inhibitor ribociclib to frontline letrozole reduced the risk of disease progression or death by 40% in elderly patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the link between circulating tumor cells and survival outcomes in metastatic breast cancer.

Sheldon M. Feldman, MD, has been named chief of the Division of Breast Surgery and Surgical Oncology, and director of Breast Cancer Services at Montefiore Einstein Center for Cancer Care at the Albert Einstein College of Medicine, Montefiore has announced. He will also join the faculty of Albert Einstein College of Medicine as a professor of clinical surgery.

The addition of pertuzumab to trastuzumab and chemotherapy reduced the risk of recurrence of invasive disease or death in patients with HER2-positive early breast cancer in the phase III APHINITY study.

John Robertson, MD, professor of Surgery, University of Nottingham, Royal Derby Hospital Centre, United Kingdom, discusses a subgroup analysis of the FALCON trial, which compared treatment with fulvestrant versus anastrozole in patients with HR-positive advanced breast cancer.

Lisa Carey, MD, discusses the current state of the science in TNBC, the potential for immunotherapy, and future treatment approaches she anticipates in the coming years.

PFS was improved with Olaparib versus standard chemotherapy in patients with <em>BRCA</em>-positive, HER2-negative breast cancer, according to findings from the phase III OLYMPIAD trial.

Breast cancer is a leading cause of cancer death in women, with 12% to 20% of cases classified as triple-negative breast cancer.

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses a study of cobimetinib plus paclitaxel in triple-negative breast cancer (TNBC).

The treatment of TNBC continues to be a challenge for physicians because of its limited treatment options, the dearth of approved targeted therapies, high mortality, and poor prognosis.

Breast cancer is a leading cause of cancer death in women, with 12% to 20% of cases classified as triple-negative breast cancer.

An axillary lymph node dissection can be avoided for patients with large, operable tumors in the breast, no clinical signs of cancer in the axillary nodes before being treated with neoadjuvant chemotherapy, and no signs of cancer following a sentinel lymph node biopsy during surgery.